HealthDay on MSN17h
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate CancerFor patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...
Hosted on MSN6d
Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoCResults from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.
Real-world data support trial data on the use of lutetium-177 PSMA-617 in patients with PSMA-positive, metastatic castration-resistant prostate cancer.
Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...
Medpage Today on MSN7d
Radiographic PFS in Metastatic CRPC More Than Doubles With Novel CombinationRadiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) more than doubled ...
Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...
Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower ...
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor ...
For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback